We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Simple DNA Test Could Identify the Risk of Inherited Diseases

By LabMedica International staff writers
Posted on 04 Mar 2010
An inexpensive, fast, and accurate test using a drop of saliva pinpoints variations at critical points along the DNA chain. More...


Researchers from the University of Edinburgh (UK) developed the new method, which is based on dynamic chemical analysis, and delivers reliable results without the need for the expensive enzymes used in conventional DNA testing. The new method allows the analysis of single-nucleotide polymorphism, indel, and abasic sites using mass spectrometry as a readout tool. Differences or omissions in the DNA code could then show if someone is healthy, susceptible to disease, or is suffering from a serious medical condition.

Currently, the test can look for genetic variations for only one disease at a time, but the researchers hope the technique could be used eventually to decode the whole human genome, which would give information about genetic variations across the whole spectrum of disease. The test takes about 30 minutes, and the methodology is suitable for the dual analysis of heterozygous samples. The study describing the new technique was published in the February 2010 issue of the journal Angewandte Chemie.

"What we have developed is a way of testing chemically; that means not using enzymes, which are the current method,” said lead author Juan Diaz-Mochon, Ph.D., of the school of chemistry. "The technology offers a speedy, cost-efficient alternative to existing methods of DNA analysis.”

"The test could help spot diseases, such as pancreatic cancer, early. It could also indicate if someone had a risk of other diseases, such as heart problems or dementia,” added coauthor Prof. Mark Bradley, Ph.D. "We plan to test the technology further, extend our collaborations with leading researchers and companies in the DNA sequencing field, and establish our first commercial operations within the next six months.”

Related Links:

University of Edinburgh



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Parainfluenza Virus Test
PARAINFLUENZA ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.